EquitySector - HealthcareVery High Risk
Regular
NAV (10-Jan-25)
Returns (Since Inception)
Fund Size
₹419 Cr
Expense Ratio
2.39%
ISIN
INF174KA1PW4
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
11 Dec 2023
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+31.90%
+32.11% (Cat Avg.)
Since Inception
+34.11%
— (Cat Avg.)
Equity | ₹415.15 Cr | 99.14% |
Others | ₹3.58 Cr | 0.86% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹62.69 Cr | 14.97% |
Cipla Ltd | Equity | ₹28.38 Cr | 6.78% |
Divi's Laboratories Ltd | Equity | ₹22.22 Cr | 5.31% |
Innova Captab Ltd | Equity | ₹18.19 Cr | 4.34% |
Jubilant Pharmova Ltd | Equity | ₹17.28 Cr | 4.13% |
Orchid Pharma Ltd | Equity | ₹16.76 Cr | 4.00% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹16.49 Cr | 3.94% |
Apollo Hospitals Enterprise Ltd | Equity | ₹16.39 Cr | 3.91% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹16.36 Cr | 3.91% |
Torrent Pharmaceuticals Ltd | Equity | ₹16.29 Cr | 3.89% |
Aurobindo Pharma Ltd | Equity | ₹15.28 Cr | 3.65% |
Dr Reddy's Laboratories Ltd | Equity | ₹15.03 Cr | 3.59% |
Lupin Ltd | Equity | ₹14.77 Cr | 3.53% |
Alkem Laboratories Ltd | Equity | ₹13.54 Cr | 3.23% |
Ajanta Pharma Ltd | Equity | ₹11.9 Cr | 2.84% |
Glenmark Pharmaceuticals Ltd | Equity | ₹11.46 Cr | 2.74% |
Zydus Lifesciences Ltd | Equity | ₹11.11 Cr | 2.65% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹10.75 Cr | 2.57% |
Krsnaa Diagnostics Ltd | Equity | ₹9.96 Cr | 2.38% |
Ami Organics Ltd | Equity | ₹9.64 Cr | 2.30% |
Fortis Healthcare Ltd | Equity | ₹8.9 Cr | 2.13% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹8.84 Cr | 2.11% |
Hikal Ltd | Equity | ₹8.65 Cr | 2.07% |
Marksans Pharma Ltd | Equity | ₹8.57 Cr | 2.05% |
Emcure Pharmaceuticals Ltd | Equity | ₹6.7 Cr | 1.60% |
Biocon Ltd | Equity | ₹6.54 Cr | 1.56% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.36 Cr | 1.52% |
Alembic Pharmaceuticals Ltd | Equity | ₹6.12 Cr | 1.46% |
Triparty Repo | Cash - Repurchase Agreement | ₹5.6 Cr | 1.34% |
Net Current Assets/(Liabilities) | Cash | ₹-2.02 Cr | 0.48% |
Large Cap Stocks
41.10%
Mid Cap Stocks
25.10%
Small Cap Stocks
31.34%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹405.51 Cr | 96.84% |
Basic Materials | ₹9.64 Cr | 2.30% |
Standard Deviation
This fund
--
Cat. avg.
15.72%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Since December 2023
Since December 2023
Since March 2024
ISIN INF174KA1PW4 | Expense Ratio 2.39% | Exit Load No Charges | Fund Size ₹419 Cr | Age 1 year 1 month | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare Index PR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹32.33 Cr | 34.1% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹890.33 Cr | 28.8% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹890.33 Cr | 27.0% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹44.16 Cr | 32.2% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹217.92 Cr | 33.8% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹217.92 Cr | 31.3% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2742.91 Cr | 32.6% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2742.91 Cr | 30.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹922.81 Cr | 29.1% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹20.52 Cr | 31.3% |
Total AUM
₹5,09,981 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Regular
NAV (10-Jan-25)
Returns (Since Inception)
Fund Size
₹419 Cr
Expense Ratio
2.39%
ISIN
INF174KA1PW4
Minimum SIP
₹100
Exit Load
No Charges
Inception Date
11 Dec 2023
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+31.90%
+32.11% (Cat Avg.)
Since Inception
+34.11%
— (Cat Avg.)
Equity | ₹415.15 Cr | 99.14% |
Others | ₹3.58 Cr | 0.86% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹62.69 Cr | 14.97% |
Cipla Ltd | Equity | ₹28.38 Cr | 6.78% |
Divi's Laboratories Ltd | Equity | ₹22.22 Cr | 5.31% |
Innova Captab Ltd | Equity | ₹18.19 Cr | 4.34% |
Jubilant Pharmova Ltd | Equity | ₹17.28 Cr | 4.13% |
Orchid Pharma Ltd | Equity | ₹16.76 Cr | 4.00% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹16.49 Cr | 3.94% |
Apollo Hospitals Enterprise Ltd | Equity | ₹16.39 Cr | 3.91% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹16.36 Cr | 3.91% |
Torrent Pharmaceuticals Ltd | Equity | ₹16.29 Cr | 3.89% |
Aurobindo Pharma Ltd | Equity | ₹15.28 Cr | 3.65% |
Dr Reddy's Laboratories Ltd | Equity | ₹15.03 Cr | 3.59% |
Lupin Ltd | Equity | ₹14.77 Cr | 3.53% |
Alkem Laboratories Ltd | Equity | ₹13.54 Cr | 3.23% |
Ajanta Pharma Ltd | Equity | ₹11.9 Cr | 2.84% |
Glenmark Pharmaceuticals Ltd | Equity | ₹11.46 Cr | 2.74% |
Zydus Lifesciences Ltd | Equity | ₹11.11 Cr | 2.65% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹10.75 Cr | 2.57% |
Krsnaa Diagnostics Ltd | Equity | ₹9.96 Cr | 2.38% |
Ami Organics Ltd | Equity | ₹9.64 Cr | 2.30% |
Fortis Healthcare Ltd | Equity | ₹8.9 Cr | 2.13% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹8.84 Cr | 2.11% |
Hikal Ltd | Equity | ₹8.65 Cr | 2.07% |
Marksans Pharma Ltd | Equity | ₹8.57 Cr | 2.05% |
Emcure Pharmaceuticals Ltd | Equity | ₹6.7 Cr | 1.60% |
Biocon Ltd | Equity | ₹6.54 Cr | 1.56% |
GlaxoSmithKline Pharmaceuticals Ltd | Equity | ₹6.36 Cr | 1.52% |
Alembic Pharmaceuticals Ltd | Equity | ₹6.12 Cr | 1.46% |
Triparty Repo | Cash - Repurchase Agreement | ₹5.6 Cr | 1.34% |
Net Current Assets/(Liabilities) | Cash | ₹-2.02 Cr | 0.48% |
Large Cap Stocks
41.10%
Mid Cap Stocks
25.10%
Small Cap Stocks
31.34%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹405.51 Cr | 96.84% |
Basic Materials | ₹9.64 Cr | 2.30% |
Standard Deviation
This fund
--
Cat. avg.
15.72%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.87
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.61
Higher the better
Since December 2023
Since December 2023
Since March 2024
ISIN INF174KA1PW4 | Expense Ratio 2.39% | Exit Load No Charges | Fund Size ₹419 Cr | Age 1 year 1 month | Lumpsum Minimum ₹100 | Fund Status Open Ended Investment Company | Benchmark Nifty Healthcare Index PR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹32.33 Cr | 34.1% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹890.33 Cr | 28.8% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹890.33 Cr | 27.0% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹44.16 Cr | 32.2% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹217.92 Cr | 33.8% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹217.92 Cr | 31.3% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2742.91 Cr | 32.6% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2742.91 Cr | 30.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹922.81 Cr | 29.1% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹20.52 Cr | 31.3% |
Total AUM
₹5,09,981 Cr
Address
2nd Floor, 12-BKC, Plot No C-12, Mumbai, 400 051
Get your portfolio reviewed by experts